Lactobacillus reuteri specifically binds to H. pylori in the stomach. The adhesion molecules on the surface of Pylopass™ recognize and attach to the surface of Helicobacter pylori. There is formation of aggregates in the stomach which are then excreted through the digestive tract and eliminated from the body. Helicobacter pylori is a human pathogen infecting about 50% of the world’s population. The average prevalence in developed countries among individuals under 40 years of age is 20%, whereas developing countries have a prevalence rate of 80 to 90%. Helicobacter pylori is associated with a number of gastrointestinal diseases, such as peptic ulcers, gastritis, and gastric cancer. The effectiveness of using probiotics in the prevention and treatment of various gastrointestinal diseases has been widely demonstrated in clinical studies. It has been found that not only live probiotics but also dead cells or even cell fractions seem sufficient to modify biological responses. The development of the inactivated DSMZ17648 Lactobacillus strain offers preventive options for patients by reducing the risk of ulcers or gastric cancer.